Home  Clinical trials Products in Development AZD3480
|
|
A number of clinical trials with AZD3480 Ongoing studies are currently in progress.
More studies will be added in due course. Additional AZD3480 Ongoing study information is available on ClinicalTrials.gov. | Study Number | Study Phase | Start Date | Recruitment Status | | D3690C00004 | Phase I | 14 Jan 2008 | Completed | | A Double-blind, Randomised, Multicentr, Placebo-controlled, 4-Ways Crossover Study to Investigate the Effect on the QT/QTc interval of Repeated and Escalating Doses of AZD3480 during 6 Days, using Moxifloxacin as a Positive Control, in Healthy Male Volunteers, CYP2D6 Extensive and Poor Metabolisers. | | D3690C00005 | Phase I | 17 Jul 2008 | Not yet Recruiting | | A double-blind, randomised, cross-over, placebo-controlled study of repeated oral doses of AZD3480 and a single dose of donepezil to evaluate the pharmacokinetic interaction between AZD3480 and donepezil in healthy extensive and poor metabolisers of CYP2D6 | | D3690C00010 | Phase II | 2 Jul 2007 | Completed | | A multi-center, double-blind, double-dummy, placebo controlled, parallel group, randomized, phase IIb proof of concept study with 3 oral dose groups of AZD3480 or donepezil during 12 weeks treatment in patient with Alzheimer's disease. | D3690C00011 | Phase II | 13 Aug 2007 | Completed | | A Multi-Center Randomized, Placebo-Controlled, Double-Blind, Parallel Group, Phase IIb Proof of Concept Study with 3 Oral Groups of AZD3480 during 12 Weeks Treatment of Cognitive Deficits in Patients with Schizophrenia | D3690C00014 | Phase I | 19 Sep 2007 | Recruiting | | A single-centre, double blind, randomised, two-way cross-over study of repeated doses of AZD3480 and single dose of warfarin to evaluate the pharmacokinetic interaction of AZD3480 and warfarin and the effect of AZD3480 pharmacodynamic in healthy male subjects (phase I) | D3690C00016 | Phase I | 13 Nov 2007 | Recruiting | | A phase I, double blind, randomised, two-way cross over, single- centre study in healthy CYP2D6 extensive metabolisers and poor metabolisers to investigate the potential of AZD3480 to inhibit cytochrome P450 1A2, 2C19, 3A4, 2C8, 2B6 and UGT1A1 activity | D3690C00017 | Phase I | 16 Oct 2008 | Recruiting | | An Open, Two Period, Single Dose, Phase I Study of the Excretion of Radioactivity, Metabolic Profiles and Pharmacokinetics Following Oral Administration of [14C]-AZD3480 and the Pharmacokinetics of AZD3480 Following Intravenous Administration to Healthy Male Volunteers with Different CYP2D6 Genotype | D3690C00018 | Phase I | 21 Jan 2008 | Completed | | An Open Label Positron Emission Tomography (PET) Study Using 2-[18F]-F-A85380 to Determine α4β2 Neuronal Nicotinic Receptor Occupancy of AZD3480 After Oral Administration to Healthy Male Subjects (Non Nicotine Users) | D3691C00001 | Phase I | 21 Jan 2008 | Recruiting | | A single-centre, double-blind, randomised, parallel group study of repeated oral doses of AZD3480/placebo and a single dose of aripiprazole to evaluate the pharmacokinetic interaction between AZD3480 and aripiprazole in healthy subjects (phase I) | TC-1734-226-CRD-005 | Phase II | 19 May 2008 | Recruiting | An exploratory Trial of AZD3480 (TC-1734) for the Treatment of Adult Attention-Deficit/Hyperactivity Disorder (ADHD) |
|
|
|
|